Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content
Figure 6 | Journal of Experimental & Clinical Cancer Research

Figure 6

From: Midkine promoter-based conditionally replicative adenovirus therapy for midkine-expressing human pancreatic cancer

Figure 6

Anti-tumor effect of Ad5MK in a Suit-2 intraperitoneal xenograft model. After intraperitoneal inoculation of 2 × 106/ml Suit-2 cells in nude mice, 2 × 109 PFU of Ad5GFP or Ad5MK, or 500 μl of PBS, was administered intraperitoneally. There was a significant difference of survival time between the Ad5MK group and the other groups (p = 0.0002 Log-rank test and p = 0.0002 by Wilcoxson's test).

Back to article page

Journal of Experimental & Clinical Cancer Research

ISSN: 1756-9966

Contact us